Treatment of Human Immunodeficiency Virus—Related Thrombocytopenia With Zidovudine

John C. Pottage, Constance A. Benson, Joel B. Spear, Alan L. Landay, Harold A. Kessler

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Human immunodeficiency virus (HIV)—related thrombocytopenia has been well described and requires therapy in about one half of the patients. Conventional modes of therapy with prednisone, danazol, immunoglobulin, and/or splenectomy have not been uniformly successful. We have administered zidovudine to three patients with HIV-related thrombocytopenia. All three patients responded with a sustained increase in their platelet counts, despite discontinuation of conventional therapy. Interruption of zidovudine therapy was associated with a decrease in platelet count. Concomitant with the elevation in platelet count with zidovudine therapy, there was a reduction in the circulating p24 antigen levels. Whether the elevations in the platelet count in these patients with HIV-related thrombocytopenia is due to the antiviral effect of zidovudine is unknown. It is clear that further studies examining the prospective use of zidovudine in the treatment of HIV-related thrombocytopenia are indicated.

Original languageEnglish (US)
Pages (from-to)3045-3048
Number of pages4
JournalJAMA: The Journal of the American Medical Association
Issue number20
StatePublished - Nov 25 1988
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Treatment of Human Immunodeficiency Virus—Related Thrombocytopenia With Zidovudine'. Together they form a unique fingerprint.

Cite this